Roivant Sciences Ltd.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $170.3M | $1.80B | $2.06B |
| FY2022 | $210.0M | $1.66B | $2.06B |
| FY2023 | $375.5M | $1.16B | $1.68B |
| FY2024 | $430.6M | $5.97B | $6.49B |
| FY2025 | — | $4.69B | $2.72B |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $170.3M | $1.80B | $2.06B |
| FY2022 | $210.0M | $1.66B | $2.06B |
| FY2023 | $375.5M | $1.16B | $1.68B |
| FY2024 | $430.6M | $5.97B | $6.49B |
| FY2025 | — | $4.69B | $2.72B |